10X Genomics EBITDA vs. Current Valuation
| TXG Stock | USD 15.90 0.42 2.71% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -205.1 M | Current Value -215.4 M | Quarterly Volatility 138.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.86 | 0.6615 |
|
|
For 10X Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of 10X Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well 10X Genomics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between 10X Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of 10X Genomics over time as well as its relative position and ranking within its peers.
10X |
10X Genomics' Revenue Breakdown by Earning Segment
Check out World Market Map.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 5.261 | Quarterly Revenue Growth (0.01) | Return On Assets (0.11) | Return On Equity (0.25) |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
10X Genomics Current Valuation vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining 10X Genomics's current stock value. Our valuation model uses many indicators to compare 10X Genomics value to that of its competitors to determine the firm's financial worth. 10X Genomics is rated fifth in ebitda category among its peers. It is rated fourth in current valuation category among its peers . At this time, 10X Genomics' EBITDA is most likely to decrease significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value 10X Genomics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.10X Current Valuation vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
10X Genomics |
| = | (205.11 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
10X Genomics |
| = | 1.56 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
10X Current Valuation vs Competition
10X Genomics is rated fourth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 13.64 Billion. 10X Genomics retains roughly 1.56 Billion in current valuation claiming about 11% of equities under Health Care industry.
10X Genomics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in 10X Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, 10X Genomics will eventually generate negative long term returns. The profitability progress is the general direction of 10X Genomics' change in net profit over the period of time. It can combine multiple indicators of 10X Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -429 K | -450.4 K | |
| Net Interest Income | 16.9 M | 17.7 M | |
| Interest Income | 16.9 M | 17.8 M | |
| Operating Income | -265.3 M | -252.1 M | |
| Net Loss | -255.1 M | -267.9 M | |
| Income Before Tax | -248.8 M | -261.2 M | |
| Non Operating Income Net Other | 7.4 M | 7.8 M | |
| Total Other Income Expense Net | 16.6 M | 17.4 M | |
| Net Loss | -149.4 M | -156.9 M | |
| Net Loss | -255.1 M | -267.9 M | |
| Income Tax Expense | 6.3 M | 3.7 M | |
| Change To Netincome | 158.6 M | 111.7 M | |
| Net Loss | (2.18) | (2.29) | |
| Income Quality | 0.06 | 0.06 | |
| Net Income Per E B T | 1.03 | 0.82 |
10X Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on 10X Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of 10X Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the 10X Genomics' important profitability drivers and their relationship over time.
Use 10X Genomics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if 10X Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in 10X Genomics will appreciate offsetting losses from the drop in the long position's value.10X Genomics Pair Trading
10X Genomics Pair Trading Analysis
The ability to find closely correlated positions to 10X Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace 10X Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back 10X Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling 10X Genomics to buy it.
The correlation of 10X Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as 10X Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if 10X Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for 10X Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your 10X Genomics position
In addition to having 10X Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Raw Materials Thematic Idea Now
Raw Materials
Companies that are involved with the development and processing of raw materials such as silver or forestry. The Raw Materials theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Raw Materials Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
To fully project 10X Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of 10X Genomics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include 10X Genomics' income statement, its balance sheet, and the statement of cash flows.